Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
0.513
-0.018 (-3.30%)
Mar 9, 2026, 3:20 PM EDT - Market open
Femasys Revenue
Femasys had revenue of $729.39K in the quarter ending September 30, 2025, with 31.44% growth. This brings the company's revenue in the last twelve months to $2.06M, up 63.53% year-over-year. In the year 2024, Femasys had annual revenue of $1.63M with 51.97% growth.
Revenue (ttm)
$2.06M
Revenue Growth
+63.53%
P/S Ratio
15.27
Revenue / Employee
$29,035
Employees
71
Market Cap
30.43M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harvard Bioscience | 87.37M |
| Retractable Technologies | 37.90M |
| Bionano Genomics | 28.72M |
| Precision Optics Corporation | 24.42M |
| Jin Medical International | 20.69M |
| Nephros | 17.93M |
| Ekso Bionics Holdings | 12.80M |
| Milestone Scientific | 8.93M |
FEMY News
- 9 days ago - Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 14 days ago - Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination - GlobeNewsWire
- 7 weeks ago - Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care - GlobeNewsWire
- 2 months ago - Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - GlobeNewsWire
- 3 months ago - PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - Business Wire
- 4 months ago - Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million - GlobeNewsWire
- 5 months ago - Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo - GlobeNewsWire
- 6 months ago - Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed® - GlobeNewsWire